Markers of Infection and Resistance in Invasive Fusariosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-19

Study Completion Date

2028-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In recent decades, invasive fusarioses have been emerging fungal pathologies with high mortality. The prognosis depends on the speed of the diagnosis, but currently biological diagnosis is mainly based on fungal culture, no specific biomarker for this microorganism is available in current clinical practice. The genus Fusarium also shows reduced sensitivity to antifungals commonly used and recommended in clinical practice, such as voriconazole or amphotericin B.

The main objective of this study is to describe the proportions of different fungal species in positive fungal cultures in patients with invasive fungal infection (IFI) or fungal keratitis. The secondary objectives are the description of the dosage of galactomannans, beta (1,3) -D-glucans and the rate of detection of DNA circulating in case / control groups for the 2 clinical forms studied. In patients with evidence of Fusarium wilt, the study will describe the distribution of the different minimum inhibitory concentrations (MIC) depending on whether or not different antifungals are taken, the vital status at 3 months, and the response or not to treatment. Finally, the presence of genetic markers will be described according to the groups of MIC values.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retrospective Study of Invasive Fungal Infections With Filamentous Fungi in Heart Transplant Patients

NCT06498310

Invasive Fungal Infections

RECRUITING

Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients

NCT05150327

Fungal Infection

COMPLETED

Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal Infections (IFI)

NCT07272915

Candidemia Aspergillosis Invasive Pneumocystosis; Pneumonia (Etiology) +1 more

COMPLETED

Identification of Serum and/or Plasma Biomarkers for the Diagnosis Prognosis and/or Prediction of Invasive Mycosis in Neutropenic Patients

NCT01907477

Neutropenic Patients

COMPLETED NA

Sautour PHRC IR 2008

NCT02859831

Mycosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fusariosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Invasive fusariosis

biomarkers

Intervention Type DIAGNOSTIC_TEST

galactomannan, betaDglucan, resistance markers

Fusarium keratitis

biomarkers

Intervention Type DIAGNOSTIC_TEST

galactomannan, betaDglucan, resistance markers

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

biomarkers

galactomannan, betaDglucan, resistance markers

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Suspicion of invasive fungal infection involving the performance of a blood culture or a skin biopsy or diagnosis of keratitis involving the taking of a cornea sample
* Fungal culture carried out on this sample
* Person having been informed of the research and not having opposed the use of their data